Drug delivery specialist with a site in Clitheroe receives £33m. funding boost

Investment totalling £33m. with leading global firm Kindeva Drug Delivery will ensure a new generation of green, low-carbon, respiratory inhalers are made in the UK, supporting efforts to grow the economy.
Watch more of our videos on Shots!
and live on Freeview channel 276
Visit Shots! now

The cash injection will create 40 full-time jobs and safeguard 218 existing full-time jobs across Kindeva’s sites in Clitheroe and Loughborough.

Read More
Family friendly music festival in Sabden raises £13,000

This is the sixth investment delivered through the Life Sciences Innovative Manufacturing Fund, which has supported UK life sciences manufacturing with £340 million in joint government and industry backing in the last financial year, and £416 million since 2021.

Drug delivery specialist Kindeva has a manufacturing facility in ClitheroeDrug delivery specialist Kindeva has a manufacturing facility in Clitheroe
Drug delivery specialist Kindeva has a manufacturing facility in Clitheroe
Hide Ad
Hide Ad

The funding comes from the Chancellor’s £650 million ‘Life Sci for Growth’ war-chest, announced in May this year, to fire up the UK’s life sciences sector and helps to deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills.

Kindeva Drug Delivery is a leading global contract development and manufacturing organization specialising in pharmaceutical drug-device combination products, such as inhalers, nebulizers and medicated patches.

Kindeva’s global chief commercial officer David Stevens said: “This joint investment creates a myriad of new opportunities for colleagues within the UK, as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation pharmaceutical products.

“Furthermore, it provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with the largest pharmaceutical companies in the world to bring the next generation of green inhalers to market, with a common goal of safeguarding access to necessary therapies for our patients and also reducing our impact on the planet.”

Related topics: